Home › Mercks Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus
 

Keywords :   


Mercks Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus

2016-06-13 16:30:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Mercks investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-334-4688orInvestor:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: to showing met primary

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.04Sherwin-Williams Reports 1Q 2024 Financial Results
29.04Power cut causes disruption at major airport
29.04New law aims to protect devices from hackers
28.04National Coalition to End Period Poverty Launched
28.04PZ Cussons To Sell St. Tropez & Aveda Launches Curl Care Line
28.04Beauty Enthusiasts Eye Burgundy Mascara
28.04Distinctive Assets Distributes Mother\'s Day in Hollywood Celebrity Gift Boxes
28.04Musk in China to discuss full self driving - reports
More »